2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|June 2, 2004
- Pharmaceutical Technology-06-02-2004
- Volume 28
- Issue 6
Microbial Testing in Support of Aseptic Processing
Author(s)Anthony M. Cundell
The role of microbial testing to ensure the sterility of aseptically filled sterile products is explained, from the product development phase to in-process monitoring to finished product testing.
Advertisement
Articles in this issue
over 22 years ago
June 2004over 22 years ago
Uniformity of Bioprocessing Equipment Manufacturingover 22 years ago
Research Tips To Find Packaging Facts Fastover 22 years ago
New Technologies Optimize Biotech Process Efficiencyover 22 years ago
Will CROs Take On the Risks of Strategic Outsourcing?over 22 years ago
Battles Escalate Over Prescription Drug Importsover 22 years ago
USP's Semi-Hemiquinquennial Meetingover 22 years ago
In the Spotlight - June 2004Advertisement
Related to this article
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Advertisement
Advertisement